Clemens Kratochwil
Overview
Explore the profile of Clemens Kratochwil including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
155
Citations
8374
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mori Y, Tamburini K, Novruzov E, Schmitt D, Mavriopoulou E, Loosen S, et al.
Ann Nucl Med
. 2025 Mar;
PMID: 40048016
Introduction: Liver fibrosis is a chronic fibrosing hepatic disorder following recurrent injury, characterized by the excessive accumulation of extracellular matrix. Early detection has a great clinical impact because 80-90% of...
2.
Nedelcovych M, Dash R, Wu Y, Choi E, Lapidus R, Majer P, et al.
Eur J Nucl Med Mol Imaging
. 2025 Jan;
PMID: 39743616
Purpose: Prostate-specific membrane antigen (PSMA) radioligand therapy is a promising treatment for metastatic castration-resistant prostate cancer (mCRPC). Several beta or alpha particle-emitting radionuclide-conjugated small molecules have shown efficacy in late-stage...
3.
Helisch A, Kratochwil C, Kleist C, Kramer S, Rosales Castillo J, Dendl K, et al.
J Nucl Med
. 2024 Oct;
65(12):1917-1922.
PMID: 39477492
Radiopharmaceutical therapies (RPTs) based on fibroblast activation protein (FAP) and FAP inhibitors (FAPIs) are a new option for progressive metastatic cancer in patients pretreated multiple times. To date, published in-human...
4.
Haberkorn U, Altmann A, Giesel F, Kratochwil C
J Nucl Med
. 2024 Aug;
65(10):1518-1520.
PMID: 39168520
No abstract available.
5.
Rathke H, Winter E, Bruchertseifer F, Rohrich M, Giesel F, Haberkorn U, et al.
J Nucl Med
. 2024 Jun;
65(7):1057-1063.
PMID: 38844358
The aim of this work is to evaluate our clinical real-world data obtained with Ac-PSMA-617 (AcPSMA), which were acquired under compassionate care regulations in patients with advanced-stage prostate cancer. The...
6.
Tulipan A, Kratochwil C, Lilleby J, Lilleby W
Urol Case Rep
. 2024 May;
54:102752.
PMID: 38779691
The development of potent novel androgen receptor inhibitors (ARi) such as apalutamide have improved the life expectancy in men with castration-resistant prostate cancer (CRPCa). However, some serious toxicity can occur...
7.
Ahmadzadehfar H, Seifert R, Afshar-Oromieh A, Kratochwil C, Rahbar K
Semin Nucl Med
. 2024 Apr;
54(4):581-590.
PMID: 38570288
This review paper highlights the transformative role of PSMA-targeted diagnostics and therapy in prostate cancer management, particularly focusing on Lu-PSMA-617, approved by the FDA and EMA for metastatic castration-resistant prostate...
8.
Sathekge M, Lawal I, Bal C, Bruchertseifer F, Ballal S, Cardaci G, et al.
Lancet Oncol
. 2024 Jan;
25(2):175-183.
PMID: 38218192
Background: Actinium-225 (Ac) prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) is a novel therapy for metastatic castration-resistant prostate cancer (mCRPC). We aimed to report the safety and antitumour activity of...
9.
Mamlins E, Scharbert L, Cardinale J, Krotov M, Winter E, Rathke H, et al.
Mol Imaging Biol
. 2023 Dec;
26(1):81-89.
PMID: 38066252
Purpose: Radiolabeled PSMA-ligands play a major role in today's nuclear medicine. Since approval of [Lu]Lu-PSMA-617 for therapy of metastatic prostate cancer, availability of Lu became bottleneck of supply due to...
10.
Cardinale J, Giesel F, Wensky C, Rathke H, Haberkorn U, Kratochwil C
J Nucl Med
. 2023 Nov;
64(10):1663-1664.
PMID: 37948188
No abstract available.